Wells Fargo & Company Issues Positive Forecast for Heartflow (NASDAQ:HTFL) Stock Price

Heartflow (NASDAQ:HTFL) had its price objective increased by equities research analysts at Wells Fargo & Company from $37.00 to $39.00 in a report released on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective points to a potential downside of 4.26% from the company’s current price.

Several other equities analysts have also recently weighed in on the stock. Freedom Capital raised shares of Heartflow to a “strong-buy” rating in a research note on Tuesday, June 30th. Piper Sandler reissued an “overweight” rating and issued a $45.00 price objective on shares of Heartflow in a research report on Friday. Stifel Nicolaus lifted their price target on Heartflow from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Friday. Weiss Ratings upgraded shares of Heartflow from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 7th. Finally, Morgan Stanley set a $40.00 target price on shares of Heartflow in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $42.00.

Heartflow Trading Up 31.4%

Shares of Heartflow stock traded up $9.72 during mid-day trading on Friday, reaching $40.73. 3,975,411 shares of the stock were exchanged, compared to its average volume of 1,434,520. The firm has a 50-day simple moving average of $28.80 and a 200 day simple moving average of $27.70. Heartflow has a fifty-two week low of $20.13 and a fifty-two week high of $42.95. The company has a market cap of $3.51 billion and a price-to-earnings ratio of -13.18.

Heartflow (NASDAQ:HTFL) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.15. The company had revenue of $64.08 million during the quarter. Heartflow’s revenue was up 47.7% on a year-over-year basis. On average, research analysts predict that Heartflow will post -0.82 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO John C.M. Farquhar sold 38,900 shares of the business’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $35.00, for a total transaction of $1,361,500.00. Following the completion of the sale, the chief executive officer owned 457,935 shares in the company, valued at $16,027,725. The trade was a 7.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Campbell Rogers sold 9,219 shares of the stock in a transaction on Monday, May 18th. The stock was sold at an average price of $28.34, for a total value of $261,266.46. Following the completion of the transaction, the insider owned 78,731 shares in the company, valued at approximately $2,231,236.54. This represents a 10.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 115,805 shares of company stock worth $3,530,609. 7.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Heartflow

A number of hedge funds and other institutional investors have recently modified their holdings of HTFL. Caitong International Asset Management Co. Ltd purchased a new position in shares of Heartflow in the 4th quarter worth about $27,000. Russell Investments Group Ltd. purchased a new stake in Heartflow in the fourth quarter worth $45,000. Essential Partners LLC bought a new stake in shares of Heartflow in the first quarter valued at $57,000. Legal & General Group Plc purchased a new position in shares of Heartflow during the 3rd quarter valued at $59,000. Finally, Strs Ohio bought a new position in shares of Heartflow during the 4th quarter worth $99,000.

Key Stories Impacting Heartflow

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Strong Q2 performance: Heartflow reported a loss of $0.07 per share, beating the $0.22 expected loss by $0.15. Revenue reached $64.08 million, an increase of 47.7% from the prior-year quarter. Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
• Positive Sentiment: Raised 2026 outlook: Management now expects full-year revenue of $246 million to $250 million, well above the approximately $230.1 million analyst consensus. The higher forecast reinforces expectations for continued demand for Heartflow’s AI-based coronary artery disease diagnostic technology.
• Positive Sentiment: Analyst upgrade: Stifel Nicolaus raised its price target from $40 to $45 and upgraded the stock to “Buy,” implying additional upside based on the reported reference price. This adds further momentum following the earnings release. Benzinga
• Neutral Sentiment: Profitability remains a concern: Although the quarterly loss was narrower than expected and significantly improved from the prior year, Heartflow remains unprofitable. Analysts currently expect a full-year loss of approximately $0.82 per share.
• Negative Sentiment: CEO stock sale: Chief Executive John C.M. Farquhar sold 22,562 shares valued at approximately $638,730, reducing his direct holdings by 4.92%. The transaction was made under a pre-arranged Rule 10b5-1 plan, which reduces its signaling value, but repeated insider selling could still weigh modestly on sentiment. Heartflow CEO Sells Shares

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.